This #Movember, we’re raising awareness of prostate cancer and the need for more innovation in advanced stages of disease, where today’s treatment options are limited. Prostate cancer remains a significant global health challenge as the most frequently diagnosed cancer in men in more than half the world. Care has evolved in the past 20 years with new technologies to diagnose and treat patients with prostate cancer and help them live longer. However, there is more to do. Learn more: https://lnkd.in/g9V46Jd6 #ProstateCancerAwareness
Thank you Novartis for highlighting such an important topic this Movember. As a recent formulation engineering graduate, I’m encouraged by the progress in prostate cancer diagnostics and treatment, although the unmet needs in advanced stages show how much innovation is still needed. Cancer is a cause that truly resonates with me, and I hope to contribute to this fight in my future work.
#ProstateCancerAwareness
Movember’s global focus on prostate cancer spotlights a critical challenge: despite advances in diagnosis and care, men with advanced disease still face limited treatment options and persistent disparities in outcomes. Prostate cancer is the world’s most common cancer among men, yet awareness and proactive health checks—like PSA testing and regular conversations with healthcare providers—remain essential to improving survival and quality of life. Innovations in imaging, targeted therapies, and survivorship support—driven by research and Movember-backed initiatives like True North—are helping more men live longer, yet there is urgent need for new breakthroughs to tackle advanced stages of the disease. The ongoing evolution in care must match the complexity of prostate cancer and the needs of those affected, especially as the Movember movement continues to accelerate patient education, advocacy, and global collaboration.
Hi Novartis team, I am currently looking for a new opportunity if any vacancy means please let me know.
While early-stage prostate cancer benefits from precision diagnostics and localized therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic bottleneck. The tumor’s adaptive resistance, coupled with its immunologically “cold” microenvironment, limits the efficacy of conventional immunotherapies.
Partilho : ^{ )
Thank you for bringing attention to this. Patients facing prostate cancer often encounter complex coverage questions along with the emotional weight of a diagnosis. Efforts that raise awareness and support education help build stronger pathways to timely care and better outcomes.
Thank you for spreading awareness on such an important topic that is critical and challenging.
Such an important initiative!
Talent Acquisition • People Intelligence • Workforce Design • AI-Driven • Curiosity-Led • Data-Obsessed • Marathoner • Nomad • Linguist • Vegetarian • Harvard I/O Psych Student • Girl dad
4dWork-in-progress… 🥸 Thank you for shining a light on this fantastic initiative to keep men’s health in the conversation!